Skip to main navigation
Skip to search
Skip to main content
Johns Hopkins University Home
Home
Profiles
Research units
Research output
Search by expertise, name or affiliation
Midostaurin approved for FLT3-mutated AML
Mark Levis
School of Medicine
Research output
:
Contribution to journal
›
Article
›
peer-review
114
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Midostaurin approved for FLT3-mutated AML'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
midostaurin
78%
Acute Myeloid Leukemia
45%
Receptor Protein-Tyrosine Kinases
16%
United States Food and Drug Administration
15%
Phosphotransferases
12%
Pharmaceutical Preparations
6%
Chemical Compounds
Midostaurin
100%
Phosphotransferase Inhibitor
30%
Tyrosine
21%
Drug
12%